EUDA drug report highlights trends and developments in psychedelics
The EU Drugs Agency (EUDA) has released its annual European Drug Report, focusing on emerging trends in the European drug market.
It includes a chapter on the growing interest in psychedelics for therapeutic use, noting that research on substances like psilocybin, MDMA, DMT, and LSD for conditions such as PTSD and treatment-resistant depression is advancing rapidly.
The report also highlights new funding developments, such as €6.5 million from Horizon Europe for psychedelic-assisted therapy research in palliative care, and funding in Czechia for psychedelic addiction treatment research.
It also notes the rise of unregulated psychedelic practices, including wellness retreats involving substances like ayahuasca and psilocybin. These practices are spreading across EU Member States with varying levels of legality and oversight, raising concerns about risks, particularly for vulnerable individuals. The EUDA calls for improved monitoring to better understand these emerging trends.
